Is the catch-up program of HPV vaccination for Japanese adult women effective or not?

Affiliations

Comment

Tetsuji Kurokawa. Cancer Sci. 2020 Apr.

. 2020 Apr;111(4):1435-1436.

doi: 10.1111/cas.14342. Epub 2020 Feb 26.

¹ Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

No abstract available

Conflict of interest statement

The author has no conflict of interest.

Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program.
Matsumoto K, Yaegashi N, Iwata T, Yamamoto K, Aoki Y, Okadome M, Ushijima K, Kamiura S, Takehara K, Horie K, Tasaka N, Sonoda K, Takei Y, Aoki Y, Konnai K, Katabuchi H, Nakamura K, Ishikawa M, Watari H, Yoshida H, Matsumura N, Nakai H, Shigeta S, Takahashi F, Noda K, Yoshikawa H; MINT Study Group. Matsumoto K, et al. Cancer Sci. 2019 Dec;110(12):3811-3820. doi: 10.1111/cas.14212. Epub 2019 Nov 4. Cancer Sci. 2019. PMID: 31596999 Free PMC article.

1. Matsumoto K, Yaegashi N, Iwata T, et al. Reduction in HPV16/18 prevalence among young women with high‐grade cervical lesions following the Japanese HPV vaccination program. Cancer Sci. 2019;110:3811–3820. - PMC - PubMed
1. The FUTURE II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. N Engl J Med. 2007;356:1915–1927. - PubMed
1. Paavonen J, Naud P, Salmerón J, et al. Effi cacy of human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women. Lancet. 2009;374:301–314. - PubMed
1. Castellsagué X, Muñoz N, Pitisuttithum P, et al. End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105:28–37. - PMC - PubMed
1. Skinner SR, Szarewski A, Romanowski B, et al. Effi cacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213–2227. - PubMed